发明名称 |
Cytokine-based fusion proteins for treatment of multiple sclerosis |
摘要 |
The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided. |
申请公布号 |
US8920808(B2) |
申请公布日期 |
2014.12.30 |
申请号 |
US200712447389 |
申请日期 |
2007.10.29 |
申请人 |
East Carolina University |
发明人 |
Mannie Mark D. |
分类号 |
A61K38/20;A61K39/00;A61K39/35;A61K47/48;C07K14/52;C12N15/63;C12N5/10;C12P21/00;C07K14/47;A61K9/00 |
主分类号 |
A61K38/20 |
代理机构 |
Myers Bigel Sibley & Sajovec, P.A. |
代理人 |
Myers Bigel Sibley & Sajovec, P.A. |
主权项 |
1. A method of treating multiple sclerosis comprising administering to a subject an effective amount of a first and at least a second fusion protein, wherein the first and the at least second fusion protein each independently comprise:
(a) an encephalitogenic determinant of an autoimmune antigen selected from the group consisting of myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG) and myelin-associated oligodendrocytic basic protein; and (b) an anti-inflammatory cytokine selected from the group consisting of an interleukin or interleukin receptor antagonist,wherein the anti-inflammatory cytokine of the first fusion protein is interleukin-2 (IL-2) and the anti-inflammatory cytokine of the at least second fusion protein is interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-13 (IL-13), interleukin-16 (IL-16), interferon-beta (IFN-β) or transforming growth factor-beta (TGF-β) and the interleukin receptor antagonist is interleukin-1RA (IL-1RA). |
地址 |
Greenville NC US |